To improve the targeted delivery of protein therapy for metastatic 4T1 breast cancer in vivo, “epidermal growth factor receptor (EGFR) and CD44 dual-targeted hyaluronic acid nanogels (EGFR/CD44-NGs)” were formulated. Here, CD44 is linked to breast carcinoma.